CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 84 enrolled
Drug / intervention
Methotrexate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04108468
NCT04108468Phase 3Completed
CompareCT.gov

An Investigator-initiated Double-blind, Parallel-group Randomised Controlled Trial of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA Using Clinical and Whole Body MRI Outcomes: the GOLMePsA Study.

The Leeds Teaching Hospitals NHS Trust·interventional·Posted Sep 30, 2019·Updated Dec 2, 2025

In Brief

A Phase 3 clinical trial evaluating Methotrexate and Golimumab for Psoriatic Arthritis. Completed, enrolled 84 participants across 1 site.

Detailed Summary

An investigator-initiated double-blind, parallel-group randomised controlled trial of Methotrexate versus GOLimumab and Methotrexate in very early PsA using clinical and whole body MRI outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesUnited Kingdom
CollaboratorsJanssen Pharmaceutica N.V., Belgium

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 30, 2019
Enrollment StartOct 27, 2015
Primary CompletionJul 1, 2023
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 6.8 years ago

Interventions

Methotrexatedrug

Methotrexate

Golimumabdrug

Simponi